Stanley T. Crooke
 | The topic of this article may not meet Wikitia's general notability guideline. |
Stanley T Crooke | |
|---|---|
| Add a Photo | |
| Born | March 28, 1945 |
| Education | MD - Baylor College of Medicine, Houston, TX, 1974
PhD Pharmacology - Baylor College of Medicine, Houston, TX, 1971 BS Pharmacy - Butler University, Indianapolis, IN, 1966 |
Stanley T. Crooke is the founding CEO of Ionis Pharmaceuticals, an RNA-targeted therapeutics company.[1] In 1989, Dr. Crooke opened Ionis with the goal of inventing a new drug discovery platform, Antisense Oligonucleotide technology. Over the years, Ionis has developed several drugs including Spinraza, which is designed to treat spinal muscular atrophy (SMA).[2] In 2020, Stan founded the N-Lorem foundation, a non-profit designed to take advantage of the technology discovered at Ionis to provide experimental treatment to patients with extremely rare genetic disorders.[3]
Early Life and Education
Stanley Crooke grew up in southwest Indianapolis.[4] Coming from a working-class family, Crooke was the first in his family to finish high school. He studied pharmacy at Butler University, and attempted law school for one week before dropping out. Crooke then attended the Baylor College of Medicine, where he completed a combined MD-PhD program in pharmacology.[4]
Career
After working at Bristol Laboratories, Crooke began working in Research and Development at GlaxoSmithKline. Crooke opened Ionis Pharmaceuticals in 1989 under the name Isis Pharmaceuticals, and served as it's CEO until 2019.[5] During this time Several antisense-oligonucleotide therapeutics were registered. Vitravene is used in the treatment of patients with cytomegalovirus retinitis (CMV).[6] Volanesorsen is used in the treatment of patients with familial chylomicronemia syndrome (FCS).[7] Kynamro is used as an orphan drug for the management of homozygous familial hypercholesterolemia (HoFH).[8] Tegsedi is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR).[9]
Dr. Crooke has also worked as an adjunct professor in the Departments of Pharmacology at the University of Pennsylvania, the Baylor College of Medicine and UCSD, the Department of Anatomy and Cell Biology at UCLA, the Department of Biology at San Diego State University.[10]
In 2020, Dr. Crooke founded the n-Lorem Foundation, a non-profit organization that focuses on creating individual experimental treatments for patients with rare genetic diseases. As a non-profit, they provide experimental antisense oligonucleotides to patients for free.[11]
| Year | Award |
|---|---|
| 2022 | Prix Galein Roy Vagellos Pro Bono Humanum Award, New York, NY[12] |
References
- ↑ "Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences". Ionis Pharmaceuticals.
- ↑ "Spinraza Treatment for Spinal Muscular Atrophy (SMA) Patients". Columbia Neurology. 2020-11-11. Retrieved 2023-01-18.
- ↑ "Leadership". n-Lorem FOUNDATION. Retrieved 2023-01-18.
- ↑ 4.0 4.1 "The Personal Journey of Stanley Crooke, the Creation and Development of Ionis, and Beyond". Oligonucleotide Therapeutics Society. 2022-09-08. Retrieved 2023-01-18.
- ↑ "Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation". Ionis Pharmaceuticals.
- ↑ "Fomivirsen - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2023-01-18.
- ↑ Kolovou, Genovefa; Kolovou, Vana; Katsiki, Niki (2022-02-13). "Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia". Journal of Clinical Medicine. 11 (4): 982. doi:10.3390/jcm11040982. ISSN 2077-0383. PMC 8880470. PMID 35207255.
- ↑ Wong, Elaine; Goldberg, Tamara (February 2014). "Mipomersen (Kynamro)". Pharmacy and Therapeutics. 39 (2): 119–122. ISSN 1052-1372. PMC 3956393. PMID 24669178.
- ↑ Gales, Luís (2019-05-21). "Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis". Pharmaceuticals. 12 (2): 78. doi:10.3390/ph12020078. ISSN 1424-8247. PMC 6631675. PMID 31117178.
- ↑ "Graduates | Pharmacology Graduate Group | Perelman School of Medicine at the University of Pennsylvania". www.med.upenn.edu. Retrieved 2023-01-18.
- ↑ "Overview". n-Lorem FOUNDATION. Retrieved 2023-01-18.
- ↑ "Roy Vagelos Pro Bono Humanum Award". www.galienfoundation.org. Retrieved 2023-03-16.
External links
This article "Stanley T. Crooke" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.